Paul Michael Watt

This inventor holds 11 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Phylogica Limited, The Mccomb Foundation, Inc.. Active years: 2006-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Michael Watt. Retrieved from https://idiyas.com/inventor/paul-michael-watt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 11)

% Patents Active = 9.1

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 76(Granted Patents)

Location History:

Mt. Claremont, AU (2006 - 2010)
Perth, AU (2007 - 2018)
Mount Claremont, AU (2013 - 2019)

Company Filing History:

The Mccomb Foundation, Inc.

patent

where one patent can have more than one assignee

Years Active: 2006-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10288601 - Method of determining, identifying or isolating cell-penetrating peptides (2019-05-14),

2. 9880151 - Method of determining, identifying or isolating cell-penetrating peptides (2018-01-30),

3. 9567373 - Methods of constructing and screening libraries of peptide structures (2017-02-14),

4. 8946381 - Compositions and uses thereof for the treatment of wounds (2015-02-03),

5. 8822409 - Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith (2014-09-02),

6. 8802634 - CD40-L Inhibitory Peptides (2014-08-12),

7. 8575070 - Methods of constructing and screening libraries of peptide structures (2013-11-05),

8. 8063012 - Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor (2011-11-22),

9. 7803765 - Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom (2010-09-28),

10. 7270969 - Methods of constructing and screening diverse expression libraries (2007-09-18),

11. 6994982 - Isolating biological modulators from biodiverse gene fragment libraries (2006-02-07),

Title: Paul Michael Watt: Innovator in Cell-Penetrating Peptides

Introduction

Paul Michael Watt is a distinguished inventor based in Mount Claremont, Australia. He holds a total of 11 patents, showcasing his significant contributions to the field of biotechnology. His work primarily focuses on the development of methods and compositions related to cell-penetrating peptides.

Latest Patents

One of his latest patents is a method for determining, identifying, or isolating cell-penetrating peptides (CPPs). This invention provides a means to identify CPPs that possess cell-type selectivity and the ability to cross the Blood Brain Barrier in animal subjects. The patent also includes CPPs and their analogs, as well as compositions that incorporate these peptides. Furthermore, it outlines methods for transporting cargo molecules across cell membranes to specific cellular locations. This innovation has potential applications in treating, preventing, and diagnosing diseases that can be addressed by the cargo molecules linked to the CPPs. Additionally, tailored peptide libraries are provided for identifying or isolating CPPs.

Career Highlights

Throughout his career, Paul has made significant strides in the biotechnology sector. He has worked with notable companies such as Phylogica Limited and The McComb Foundation, Inc. His expertise in the field has led to advancements that could revolutionize therapeutic approaches.

Collaborations

Paul has collaborated with esteemed colleagues, including Richard Hopkins and Wayne Robert Thomas. These partnerships have contributed to the development of innovative solutions in biotechnology.

Conclusion

Paul Michael Watt's contributions to the field of cell-penetrating peptides highlight his role as a leading inventor in biotechnology. His innovative methods and compositions have the potential to impact medical treatments significantly.

Profile summary based on public USPTO records.